|
Key figures – 2nd quarter 2010 |
|
|
|
|
XLS |
|
|
|
|
|
|
|
|
EUR million |
Pharma- ceuticals |
Chemicals |
Corporate and Other |
Total |
Change |
|
Total revenues |
1,564.4 |
643.6 |
– |
2,208.0 |
15.6 |
|
Gross margin |
1,297.2 |
393.5 |
– |
1,690.8 |
21.5 |
|
Research and development |
–302.2 |
–36.5 |
–0.1 |
–338.8 |
–0.5 |
|
Operating result |
158.2 |
166.0 |
2.0 |
326.2 |
76.8 |
|
Exceptional items |
– |
– |
–1.2 |
–1.2 |
– |
|
Earnings before interest and tax (EBIT) |
158.2 |
166.0 |
0.8 |
325.0 |
76.2 |
|
EBIT before depreciation and amortization (EBITDA) |
350.0 |
208.6 |
1.3 |
559.9 |
38.4 |
|
Return on sales in % |
10.1 |
25.8 |
– |
14.8 |
|
|
Free cash flow |
258.6 |
174.0 |
–76.2 |
356.4 |
– |
|
Underlying free cash flow |
258.6 |
174.0 |
–72.7 |
359.9 |
– |
|
Underlying free cash flow on revenues (FCR) in % |
16.5 |
27.0 |
– |
16.3 |
|
Print this page